Head-to-Head Comparison of Kesimpta vs Ocrevus Treatment in Patients with MS
Real-world study results presented at the 2024 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) demonstrated similar persistence and adherence of Kesimpta (ofatumumab; Novartis, East Hanover, NJ) treatment compared with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) treatment in patients with multiple sclerosis (MS). Kesimpta is self-administered subcutaneously once-monthly, whereas Ocrevus is an infusion therapy administeredevery 6 months.
Researchers conducted the retrospective cohort study using Optum Clinformatics claims data (from August 2019 through May 2023) which included adults (N=498) with ≥ 1 inpatient or ≥ 2 outpatient MS diagnoses ≥ 30 days apart; ≥ 1 Kesimpta or Ocrevus claim; and continuous enrollment ≥ 1 year before and ≥ 2 years after first Kesimpta or Ocrevus claim. Individuals treated with Kesimpta were matched 1:1 on propensity score to individuals treated with Ocrevus. Persistence, defined as the number of days from index date until treatment discontinuation, was assessed using the Kaplan-Meier approach. Discontinuation was defined as a gap ≥ 60 days of index therapy or switch to another DMT. Researchers estimated adherence based on the proportion of days covered (PDC) and defined adherence as PDC ≥ 0.8.
- The proportions of patients persistent at 18 and 24 months post index in the matched Kesimpta vs Ocrevus cohorts were 69% vs 70% (P=1.00) and 63% vs 59% (P=.62), respectively.
- The proportions of patients who were adherent at 18 and 24 months post index in the matched Kesimpta vs Ocrevus cohorts were 77% vs 74% (P=.74) and 71% vs 67% (P=.54), respectively.